Summary of Significant Accounting Policies - Schedule of Reconciliation of the Company's Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Summary of Significant Accounting Policies [Line Items]
General and administrative expenses	$ 7,459	$ 3,008
Research and development expenses
Total research and development expenses	14,645	3,421
Total operating loss	(22,104)	(6,429)
Non-operating income	3,050	1,123
Net loss	(19,054)	(5,306)
Operating Segments [Member]
Summary of Significant Accounting Policies [Line Items]
General and administrative expenses	7,459	3,008
Research and development expenses
Total direct research and development expenses	11,649	1,913
Total indirect and unallocated research and development expenses	2,996	1,508
Total research and development expenses	14,645	3,421
Total operating loss	(22,104)	(6,429)
Non-operating income	3,050	1,123
Net loss	(19,054)	(5,306)
Schizophrenia programs | Operating Segments [Member]
Research and development expenses
Total direct research and development expenses	5,813	1,260
Bipoar depression programs | Operating Segments [Member]
Research and development expenses
Total direct research and development expenses	3,006	0
Formulation and CMC | Operating Segments [Member]
Research and development expenses
Total direct research and development expenses	2,329	653
Preclinical and other direct expenses | Operating Segments [Member]
Research and development expenses
Total direct research and development expenses	501	0
Personnel-related | Operating Segments [Member]
Research and development expenses
Total indirect and unallocated research and development expenses	2,115	1,253
Consulting and other | Operating Segments [Member]
Research and development expenses
Total indirect and unallocated research and development expenses	$ 881	$ 255